Regenerative drugs or medicines are used to heal body tissues or organs from within. The process is called rejuvenation in which these medicines repair the damaged body organs which otherwise cannot heal naturally. Regenerative medicines also help in replacement where healthy cells, tissues, or organs are used from a dead or healthy donor to replace damaged cells, tissues, or organs. The other way to heal damaged tissue with these medicines is by delivering healthy cells or tissues to diseased or damaged cells in order to retain the body’s normal functioning which is known as regeneration.
Regenerative drugs also increase the possibility of growing organs in lab conditions, where cells from the patient’s own body can be used for regeneration which can reduce the chances of organ transplant rejection. Companies like Baxter International, Stryker Corporation, Medtronic plc., Cryolife, Inc., and Organogenesis, Inc (Advanced Biohealing) are among the major key players of the global regenerative drugs market.
On the basis of types, the global regenerative drugs market is segmented as synthetic, biologically derived, and genetically derived.
On the basis of materials, the global regenerative drugs market is segmented as biodegradable synthetic polymers, scaffold, hydrogel & collagen, transgenic, and fibroblasts.
On the basis of application, the global regenerative drugs market is segmented as cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others.
End-users of the global regenerative drugs market include hospitals, biomedical laboratories, and research centers.
Geographically, the global regenerative drugs market is segmented as North America, South America, Europe, the Middle East, and Asia Pacific region. Germany, France, and the UK are the major hubs that have a significant European commercial sector for regenerative medicines. These include mostly cell-based therapies from the patient’s own body and also from unrelated donors.